SeaStar Medical Conference Summary Company Overview - **Company Name**: SeaStar Medical - **Ticker Symbol**: ICU (NasdaqCM) - **Focus**: Treating hyperinflammation in critically ill patients, particularly those facing organ failure or life-threatening conditions such as Acute Kidney Injury and cardiovascular diseases [4][5] Core Products and Pipeline - **FDA-Approved Product**: QUELIMMUNE for Children - **Pipeline**: Includes the Selective Cytopheretic Device (SCD), which has received Breakthrough Device designation from the FDA for various applications [4][5] - **Market Opportunity**: Approximately 1 million patients annually could benefit from SCD, with significant revenue potential from capturing even a modest market share [5] Clinical Data and Efficacy - **SCD Mechanism**: A therapeutic medical device that neutralizes overactive immune cells, reducing mortality and dialysis dependency [6][10] - **Pediatric Study Results**: - Registration study with 22 patients showed a 50% improvement in survival rates (from 50% to 77%) and no long-term dialysis patients at Day 60 [14][15] - SAVE Registry confirmed similar results in real-world settings, with a reduction in mortality and dialysis dependency [15][16] - **Regulatory Updates**: FDA approved a reduction in the number of patients required for the SAVE Registry from 300 to 50, with 50 patients now enrolled [17][18] Commercial Strategy - **Customer Base Growth**: - End of 2024: 2 active customers - End of 2025: 10 customers - Goal for 2026: Double the customer base [22] - **Target Market**: Focus on the top 50 children's hospitals in the U.S., which represent half of the eligible patient population [22][23] Ongoing Trials - **NEUTRALIZE-AKI Trial**: - A randomized controlled study with 339 patients, currently 40% enrolled [25] - Primary endpoints include mortality rates and dialysis dependency [26] - Expected to complete enrollment by the end of 2026, with top-line data available in the first half of 2027 [29] Competitive Advantage - **Comparison with Standard Care**: Current standard of care (Continuous Renal Replacement Therapy) has a 50% mortality rate and is not disease-modifying. SCD aims to improve outcomes significantly [34] - **Economic Benefits**: QUELIMMUNE can reduce ICU length of stay and overall healthcare costs, potentially saving hospitals $40,000 to $50,000 per patient [35] Future Opportunities - **Cardiorenal Syndrome**: SCD may help patients bridge to LVAD or transplant by reducing inflammation [37] - **Regulatory Pathways**: Plans to submit modular pieces for PMA to expedite the approval process [30][31] Financial Overview - **Revenue Projections**: Expected to generate over $1 million in revenue for QUELIMMUNE in 2025, with a goal to double that in 2026 [40] - **Cash Position**: As of November, approximately $13.5 million in cash, with a monthly burn rate of $1 million to $1.3 million [41] Key Milestones for Investors - Completion of NEUTRALIZE-AKI enrollment - Doubling the customer base for QUELIMMUNE - Progress in NEUTRALIZE-CRS study and potential regulatory applications [50][51]